Clinical Trials Logo
  1. Home
  2. Chikungunya Virus Infection
  3. NCT04909411

Consequences of a Maternal-fetal Chikungunya Virus Infection — CHIK13+  

Chikungunya Virus Infection Clinical Trial

Official title:
Consequences of a Maternal-fetal Chikungunya Virus Infection. Neurocognitive and Sensory Assessment Around the Age of 13.

Clinical Trial Summary

Chikungunya is an infectious disease caused by an alphavirus transmitted by the Aedes mosquitoes which has known a worldwide expansion since its re-emergence in 2004. Regarding to an unprecedented epidemic, Reunionese pediatricians described in 2005-2006 a vertical maternal-fetal transmission of this virus, at the time of childbirth. Since then, this mode of transmission has been widely confirmed, with an absolute risk estimated between 15.5% and 48.3%. The main consequences for the child are neuromotor, neurosensory or neurocognitive. They were studied around the age of 2 in 33 children in the CHIMERE cohort, as well as at the age of 5 in a small fraction of these children followed at the C.A.M.S.P (Center for Early Medico-Social Action). The results suggested an overall delay in psychomotor acquisitions secondary to neonatal infection, affecting the functions of the prefrontal region (in particular coordination and language). Performance was correlated with the severity of the clinical presentation (more severe in case of encephalitis or encephalopathy) while remaining suboptimal in children with uncomplicated infection. During neurodevelopmental monitoring, other disturbing traits complemented the spectrum of problems presented by these children, such as microcephaly, cerebral palsy, epilepsy, interaction disorder or attention deficit disorder. At around age 10, the investigators reassessed 21 of these children using the Childhood Cognitive Function and Learning (EDA) screening test. The investigators would now like to confirm and characterize their impairments using a battery of confirmatory tests around the age of 13.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04909411
Study type Interventional
Source Centre Hospitalier Universitaire de la Réunion
Contact
Status Completed
Phase N/A
Start date January 13, 2020
Completion date October 12, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02230163 - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Phase 1/Phase 2
Completed NCT04546724 - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults Phase 3
Terminated NCT04455919 - Yoga for Chronic Chikungunya N/A
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting NCT04441905 - Phase 1 Study of SAR440894 vs Placebo Phase 1
Completed NCT02562482 - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Phase 2
Completed NCT03028441 - Phase I Trial of Measles Vectored Chikungungya Vaccine Phase 1
Completed NCT03807843 - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) Phase 2
Completed NCT04786444 - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Phase 3
Completed NCT02553369 - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection N/A
Recruiting NCT06106581 - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years Phase 2
Recruiting NCT06007183 - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination Phase 3
Completed NCT03635086 - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) Phase 2
Completed NCT02861586 - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Phase 2
Active, not recruiting NCT04838444 - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553) Phase 3
Completed NCT03483961 - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Phase 2
Recruiting NCT06028841 - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV) Phase 3